Skip to content

Stoke Therapeutics

US · STOK #2942 by market cap Listed 2019
26.81 -0.12 -0.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 5.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
123.01% -5.58pp
Institutions
237 -6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund72.57%
Hedge Fund33.86%
Public Company11.15%
VC/PE Fund4.16%
Individual/Insider3.65%
Government Pension Fund0.36%
Private Company0.35%
Insurance Company0.26%
Sovereign Wealth Fund0.25%

Top holders as of 2026-09-30

BlackRock 9.71% · 6.35M sh
RTW Investments, LP 8.60% · 5.62M sh
T. Rowe Price Group, Inc. 7.76% · 5.08M sh
FMR 7.65% · 5.00M sh
Lynx1 Capital Management LP 6.17% · 4.04M sh
Redmile Group, LLC 6.03% · 3.95M sh
BVF Partners L.P. 5.52% · 3.61M sh
Wellington Management Group 5.38% · 3.52M sh
Baker Bros. Advisors LP 5.10% · 3.34M sh
Morgan Stanley 4.91% · 3.21M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 26 sells

NameRoleStake
Seth Harrison Independent Director 2.87%
Adrian Krainer Co-Founder & Independent Director 0.43%
Edward Kaye Former Advisor & Director 0.19%
Arthur Tzianabos Chairperson 0.05%
Arthur Levin Independent Director 0.03%
Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel 0.03%
Barry Ticho Chief Medical Officer 0.02%
Jason Hoitt Chief Patient Officer 0.02%
Thomas Edward Leggett Chief Financial Officer 0.02%
Ian Smith Chief Executive Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-01 Barry Ticho Chief Medical Officer Automatic Disposition -7,195 $26.38–26.99
2026-10-01 Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel Automatic Disposition -627 $26.33
2026-09-30 Barry Ticho Chief Medical Officer Automatic Disposition -1,051 $26.16
2026-09-22 Alexander Cumbo Director Other Derivative Acquisition +39,674 $26.11
2026-08-31 Barry Ticho Chief Medical Officer Automatic Disposition -5,545 $30.51–31.06
2026-08-17 Edward Kaye Former Advisor & Director Derivative Exercise and Sale -12,567 $32.01–32.47
2026-08-17 Barry Ticho Chief Medical Officer Derivative Exercise and Sale -4,767 $32.01–32.47
2026-08-17 Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel Derivative Exercise and Sale -2,861 $32.01–32.47
2026-08-13 Edward Kaye Former Advisor & Director Derivative Exercise and Retained +13,683 --
2026-08-13 Barry Ticho Chief Medical Officer Derivative Exercise and Retained +5,233 --
2026-08-13 Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel Derivative Exercise and Retained +3,139 --
2026-08-02 Barry Ticho Chief Medical Officer Automatic Disposition -7,176 $28.95–29.45
2026-07-15 Seth Harrison Independent Director Other Derivative Acquisition +151,595 $10.90–40.37
2026-07-15 Seth Harrison Independent Director Other Derivative Disposition -151,595 $10.90–40.37
2026-07-14 Thomas McCauley Chief Scientific Officer Other Derivative Acquisition +225,000 $29.91
2026-06-30 Barry Ticho Chief Medical Officer Automatic Disposition -7,228 $32.62–33.27
2026-06-15 Jonathan Allan Corporate Secretary, Compliance Officer & General Counsel Automatic Disposition -1,457 $29.95
2026-06-02 Seth Harrison Independent Director Other Derivative Acquisition +17,786 $29.46
2026-06-02 Arthur Levin Independent Director Other Derivative Acquisition +17,786 $29.46
2026-06-02 Julie Smith Independent Director Other Derivative Acquisition +17,786 $29.46

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Stoke Therapeutics discussion 0 comments

Add a comment